Stock Events

Stock Events

XOMA Royalty 

$43.74
70
+$0.00+0% Wednesday 03:06

Statistics

Day High
43.74
Day Low
43.74
52W High
43.74
52W Low
31.37
Volume
1
Avg. Volume
-
Mkt Cap
520.94M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

30JulExpected
Q3 2025
Q1 2026
Q2 2026
-0.04
0.21
0.45
0.7
Expected EPS
0.17605
Actual EPS
N/A

Financials

60.81%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
52.15MRevenue
31.71MNet Income

Analyst Ratings

39.00Average Price Target
The highest estimate is 39.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals competes in the biotechnology industry focusing on developing and commercializing medicines for serious medical conditions, similar to XOMA's focus on antibody-based therapeutics.
AMGEN
AMGN
Mkt Cap237.52B
Amgen is a biopharmaceutical company that discovers, develops, manufactures, and delivers innovative human therapeutics, competing directly with XOMA in the biotech sector.
Biogen
BIIB
Mkt Cap32.03B
Biogen competes with XOMA in the biotechnology field, focusing on developing therapies for neurological and neurodegenerative diseases.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences is a biopharmaceutical company that researches, develops, and commercializes drugs in areas similar to XOMA, making them direct competitors.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.91B
Vertex Pharmaceuticals is involved in creating new possibilities in medicine to cure diseases and improve people's lives, competing with XOMA in the biotech innovation space.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.61B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with XOMA in the development of novel therapeutics.
Incyte
INCY
Mkt Cap25.91B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, making it a competitor in the biopharmaceutical space alongside XOMA.
Nektar Therapeutics
NKTR
Mkt Cap2.53B
Nektar Therapeutics is involved in developing new treatment options in various therapeutic areas, competing with XOMA in the innovation of biologic drugs.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.91B
BioMarin Pharmaceutical focuses on developing and commercializing innovative biopharmaceuticals for rare diseases, competing with XOMA in targeting niche markets with specialized treatments.

About

XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.
Show more...
CEO
ISIN
US98419J2069

Listings

STU
DE
X0M1.STU
BOATS
BOATS
XOMAO.BOATS
BOATS
BOATS
XOMA.BOATS

0 Comments

Share your thoughts

FAQ

What is XOMA Royalty stock price today?▼
The current price of XOMA.BOATS is $43.74 USD — it has increased by +0% in the past 24 hours. Watch XOMA Royalty stock price performance more closely on the chart.
What is XOMA Royalty stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange XOMA Royalty stocks are traded under the ticker XOMA.BOATS.
What is XOMA Royalty market cap?▼
Today XOMA Royalty has the market capitalization of 520.94M
What is XOMA Royalty revenue for the last year?▼
XOMA Royalty revenue for the last year amounts to 52.15M USD.
What is XOMA Royalty net income for the last year?▼
XOMA.BOATS net income for the last year is 31.71M USD.
In which sector is XOMA Royalty located?▼
XOMA Royalty operates in the Other sector.
When did XOMA Royalty complete a stock split?▼
The last stock split for XOMA Royalty was on October 18, 2016 with a ratio of 1:20.